UNITY Biotechnology (UBX)
(Delayed Data from NSDQ)
$1.44 USD
-0.04 (-2.70%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $1.44 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
UNITY Biotechnology, Inc. [UBX]
Reports for Purchase
Showing records 61 - 80 ( 102 total )
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
We are reiterating our Buy rating, but lowering our 12-month target price from $4 to $3/share on UNITY Biotechnology
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Visibility for UBX1325 in DME and wAMD; Looking to Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Q1: Counting Down the Days Until 12wk Ph2 Data for UBX1325/DME in Mid ''22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Post-ARVO: Setting Expectations for 12wk Ph2 UBX1325/ DME Data in Mid ''22
Provider: Wedbush Securities Inc.
Analyst: AROUNIAN Y
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Presentations at ARVO; First Patient Dosed in Ph2 for UBX1325/wAMD
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Completed Enrollment in Ph2a BEHOLD Trial for UBX1325/DME; 12wk Data in Mid ''22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Considerations for UBX1325 Phase 2 Top-Line Readouts in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY21: Looking Ahead to Key Value-Driving UBX1325 Catalysts in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Angio 2022: Keeping Safety First While Advancing Towards Extended Duration
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Focusing on What Matters - UBX1325 Top Line Expected Mid-2022; Streamlined Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Key UBX1325 and Tie2/VEGF Bispecific Catalysts Covered by Extended Cash Runway
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Momentum Building for UBX1325 Ahead of Ph2 Readouts in DME, wAMD in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Getting at the Essence with Senescence; Initiating OP & $4 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department